Analysts Are Bullish on These Healthcare Stocks: Achieve Life Sciences (ACHV), BeOne Medicines (ONC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Achieve Life Sciences (ACHV – Research Report) and BeOne Medicines (ONC – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Achieve Life Sciences (ACHV)

Lake Street analyst Thomas Flaten maintained a Buy rating on Achieve Life Sciences today and set a price target of $11.00. The company’s shares closed last Friday at $4.20.

According to TipRanks.com, Flaten is a 5-star analyst with an average return of 15.8% and a 53.8% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Rapid Micro Biosystems, and Aquestive Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Achieve Life Sciences with a $14.60 average price target, which is a 267.8% upside from current levels. In a report issued on October 17, Raymond James also maintained a Buy rating on the stock with a $20.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BeOne Medicines (ONC)

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on BeOne Medicines, with a price target of $383.00. The company’s shares closed last Friday at $316.42.

According to TipRanks.com, Laaman is a 4-star analyst with an average return of 8.7% and a 61.8% success rate. Laaman covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Recursion Pharmaceuticals, and BioMarin Pharmaceutical. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeOne Medicines with a $365.03 average price target, implying a 17.6% upside from current levels. In a report issued on October 8, J.P. Morgan also maintained a Buy rating on the stock with a $385.00 price target.

Read More on ACHV:

Disclaimer & DisclosureReport an Issue

• Achieve Life Sciences appoints Atkisson as Chief Legal Officer
• Morning Movers: Regional banks in focus after reporting Q3 results
• Achieve Life Sciences receives FDA CNPV for cytisinicline
• Achieve Life Sciences: Promising Prospects in Vaping Addiction Treatment with Cytisinicline
• Achieve Life Sciences Announces Leadership Change